Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medtronic plc (NYSE: MDT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, giving investors and analysts a detailed view of its financial condition, capital structure, governance, and material events. As an issuer with ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, Medtronic files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A, and specialized forms such as Form 25 for the removal from listing of specific debt securities.
Medtronic’s Form 8-K filings cover topics such as quarterly financial results, debt offerings, redemptions of senior notes, amendments to its Memorandum and Articles of Association, changes in board composition and executive roles, and other material definitive agreements. For example, recent 8-Ks describe euro-denominated senior notes due 2030 and 2045, their guarantees by Medtronic plc and affiliates, and the use of proceeds to repay existing notes. Other current reports document National Coverage Determinations, financial guidance updates, and dividend-related actions referenced in company news releases.
The company’s proxy statements (DEF 14A) outline its corporate governance structure, director elections, executive compensation programs, and shareholder proposals, including amendments to Articles of Association and capital reduction measures under Irish law. Form 25 filings relate to the delisting of specific classes of guaranteed senior notes once they are redeemed or otherwise withdrawn from the exchange, and do not affect the listing of MDT ordinary shares.
On this page, Stock Titan pairs Medtronic’s filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand items such as new debt issuances, changes in capital structure, or governance amendments. You can review 10-K and 10-Q reports for segment performance and risk disclosures, scan 8-Ks for notable events, and monitor registration statements and S-1 filings, such as the proposed IPO of the MiniMed diabetes business, to follow Medtronic’s strategic and financial decisions over time.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported routine equity compensation activity. On April 27, 2026, she acquired 1,508 Ordinary Shares at $0.00 per share as a grant of restricted stock units that vest in three annual installments beginning one year from the grant date.
On April 28, 2026, 318 Ordinary Shares were disposed of at $81.90 per share, representing shares withheld to pay taxes upon vesting of previously granted restricted stock units, rather than an open-market sale. After these transactions, she directly owned 13,262 Ordinary Shares, including 106 shares acquired through dividend reinvestment since her last report.
Medtronic plc director Kendall J. Powell reported routine equity compensation activity. On April 27, 2026, he received a grant of 2,111 ordinary shares in the form of restricted stock units, which vest on the one-year anniversary of the award date. When previously granted restricted stock units vested, 207 shares of Medtronic ordinary shares were withheld at $81.90 per share to cover tax obligations rather than sold on the open market. After these transactions, Powell directly holds 51,380 ordinary shares, including 854 shares acquired through dividend reinvestment since his last report.
Medtronic plc director Elizabeth G. Nabel reported routine equity compensation activity in company ordinary shares. She received an award of 2,111 restricted stock units, which vest on the one-year anniversary of the award date. The filing also reports 207 shares withheld to cover taxes upon the vesting of previously granted restricted stock units, a non‑market, tax-withholding disposition rather than an open-market sale. Following these transactions, she directly holds 19,584 ordinary shares, including 65 shares acquired through dividend reinvestment since her last report.
Medtronic plc director Kevin E. Lofton reported routine equity compensation activity involving Ordinary Shares. On April 27, 2026, he acquired 2,111 shares at $0.00 per share as a grant of restricted stock units that vest on the one-year anniversary of the award date.
On April 28, 2026, 207 shares were withheld at $81.90 per share to cover taxes upon vesting of previously reported restricted stock units, a tax-withholding disposition rather than an open-market sale. Following these transactions, he directly holds 10,140 Ordinary Shares, which include 65 shares acquired through dividend reinvestment since his last report.
Medtronic plc director Lewis Gregory P reported routine equity compensation activity. On April 27, 2026, he acquired 2,111 Ordinary Shares through a grant of restricted stock units that vest on the one-year anniversary of the award date. The position also now includes 65 shares acquired through dividend reinvestment since his last report. On April 28, 2026, 207 shares were withheld at $81.90 per share to cover taxes upon the vesting of previously granted restricted stock units, a non-market disposition. After these transactions, he directly holds 5,754 Ordinary Shares.
Lee Joon Sup reported acquisition or exercise transactions in this Form 4 filing.
Medtronic plc reported that director Lee Joon Sup received an equity award of 1,803 ordinary shares in the form of restricted stock units. These units were granted at no cash cost and will vest on the one-year anniversary of the award date. Following this grant, Lee directly holds 1,803 ordinary shares.
Jellison William R reported acquisition or exercise transactions in this Form 4 filing.
Medtronic plc director William R. Jellison received an equity award of 1,444 ordinary shares at a price of $0.00 per share. This reflects a grant or award, not an open-market purchase. Following the award, he directly owns 6,444 ordinary shares.
According to the footnote, the grant represents restricted stock units that vest on the one-year anniversary of the award date, tying the compensation to continued service over that period.
Medtronic plc director Randall J. Hogan reported routine equity compensation activity. He received an award of 2,111 ordinary shares in the form of restricted stock units that vest on the one-year anniversary of the award date. In a related move, 207 shares were withheld to cover tax obligations when previously granted restricted stock units vested, rather than being sold on the open market. Following these transactions, he directly holds 48,998 ordinary shares, which includes 65 shares acquired through dividend reinvestment since his last report.
Groetelaars John P reported acquisition or exercise transactions in this Form 4 filing.
Medtronic plc director John P. Groetelaars received a stock award rather than buying shares on the market. He was granted 1,444 ordinary shares on a Form 4 report, at a stated price of $0.00 per share, as compensation.
The award represents restricted stock units that vest on the one-year anniversary of the grant date, so he must remain eligible through that period to receive the shares. Following this grant, his directly held position reported in this filing is 1,444 ordinary shares, reflecting a small, routine equity award for a board member.
Medtronic plc director Lidia Fonseca reported routine equity compensation activity. She received an award of 2,111 ordinary shares in the form of restricted stock units that vest on the one-year anniversary of the award date.
Upon vesting of previously granted restricted stock units, 207 shares were withheld to cover taxes at a price of $81.90 per share. After these transactions, she directly owns 7,644 Medtronic ordinary shares, which includes 65 shares acquired through dividend reinvestment since her last report.